Sep 21, 2022 / 03:00PM GMT
Victoria Rutherford -
Hello, everyone. This is Victoria Rutherford from Adelaide Capital. Thanks for joining us today. We're here with Ken d'Entremont and Marcel Konrad, CEO and CFO of Medexus Pharmaceuticals.
Before we begin, I would like to remind everyone that this discussion will include forward-looking information that is based on management's current information and assumptions and is subject to risks and uncertainties that could cause actual results to differ materially from historical or anticipated results.
This discussion may also reference non-IFRS financial measures or non-GAAP measures, including references to adjusted net loss and adjusted EBITDA. These measures do not have a standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.
For more information about forward-looking information and non-GAAP measures and a reconciliation of adjusted net loss and adjusted EBITDA to net loss, refer to Medexus' most recent management discussion and analysis. Medexus' MD&A and other filings are available on the company's
Medexus Pharmaceuticals Inc Investor Update Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers